GSK Settles Zantac Lawsuits: A New Chapter for the Controversial Drug
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that certain versions might contain impurities linked to cancer,
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
The FTSE 100 index traded up 25.77 points, 0.3%, at 8,269.51. The FTSE 250 slipped 12.69 points, 0.1%, at 20,809.69, and the AIM All-Share down just 0.19 of a point at 736.47.
John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...
When Investors Make Decisions in Gsk Plc American Depositary Shares (each Representing Two) GSK Opportunities Surface ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback